Kendle Strengthens European Leadership Team With Appointment of Sally Osmond, Vice President, Europe, Middle East and Africa

CINCINNATI, Sept. 28 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced the appointment of Sally Osmond as Vice President, Europe, Middle East and Africa.  Osmond will provide senior-level leadership for the Company's Phase II-IV clinical operations throughout this important region, driving overall corporate performance and customer focus.  Osmond brings to Kendle more than 30 years of clinical trial management and operations leadership experience and will be based in the Company's Camberley, United Kingdom office.  She will report to Senior Vice President and Chief Operating Officer Stephen Cutler, PhD.

"Success in Europe, Middle East and Africa is essential to Kendle's continued growth as a top-tier global CRO," said Dr. Cutler. "We look forward to Sally's leadership as we continue to focus on broadening and deepening our capabilities in the region and across our global footprint to strengthen our position as a strategic partner."

Osmond's extensive industry experience includes multiple executive roles at multi-national CROs such as Quintiles, where she served most recently as Vice President and Business Leader for Quality in Clinical Research.  During her tenure at Quintiles she held a number of positions of increasing responsibility, including Vice President and Global Head, Project Coordination Center; Vice President, Late Phase Operations; Late Phase Head of Project Coordination; European Head of Late Phase Operations; Customer Program Director; and Group Project Director for Internal Medicine.  Prior to joining Quintiles, Osmond was Chief Operating Officer at UCTi,  a global central laboratory, where she served as Vice President, Sales and Marketing; General Manager for Europe; and Head of Business Development.

The addition of Osmond to Kendle's global leadership team reinforces the Company's already strong presence throughout Europe, where it has maintained operations since 1997. Since 2004, European operations have accounted for approximately 40 percent of Kendle's annual revenues each year. The Company is widely recognized as a leader in clinical development in Europe and recently was named one of the "Top CROs to Work With" in the CenterWatch 2010 Survey of European Investigative Sites.  

Osmond's appointment follows a series of recent strategic appointments by Kendle in the region to drive continued delivery of high-quality Phase I-IV services for the Company's biopharmaceutical customers.  Rosie McKellar, a 20-year veteran of the clinical development industry, joined Kendle in early September as Regional Director, On-Site Monitoring, providing regional leadership for on-site monitoring services.  John MacDonald, also a 20-year industry veteran, joined the Company in August as Executive Director, New Business Development, Europe, responsible for leading marketing and sales efforts in the region, with emphasis on continued expansion of strategic customer relationships.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.

Forward-Looking Statements

Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995. Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including the statements contained herein regarding anticipated trends related to Kendle's European operations and their leadership are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC.  All information in this press release is current as of Sept. 28, 2010. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

SOURCE Kendle International Inc.